Jain Global’s Entrada Therapeutics TRDA Stock Holding History

Jain Global’s Portfolio TRDA Stock Details TRDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-11,954	Closed	-$69.3K	–	1523
2025 Q3	$69.3K	Buy	+11,954	New	+$69.9K	﹤0.01%	951

Other funds holding TRDA

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jain Global's TRDA Position: Q4 2025 in Review

Jain Global sold out of Entrada Therapeutics (TRDA) in Q4 2025, closing a stake of 11,954 shares — an estimated $69.3K sold.

Jain Global first reported a position in TRDA in Q3 2025 and held it in 1 quarter. The position peaked at $69.3K in Q3 2025. 114 funds tracked by Wall St. Rank hold TRDA as of Q4 2025.

Jain Global reported no remaining Entrada Therapeutics position as of Q4 2025 after selling out during the quarter.
Jain Global sold 11,954 Entrada Therapeutics shares in Q4 2025, an estimated $69.3K.
Jain Global first reported a position in Entrada Therapeutics in Q3 2025 and held it in 1 quarter.
Jain Global's Entrada Therapeutics position peaked at $69.3K in Q3 2025.
114 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q4 2025.

Based on Jain Global's 13F filing for Q4 2025, filed 17 Feb 2026.